Posts related to ‘Pharmaceuticals’

52-Week High Club (DDS, DBRN, SJM, MRK)

Dillard’s Inc. (NYSE: DDS) rose as high as over 10% to a yearly high of $15.79 after the department-store chain was upgraded by Deutsche Bank AG.  

Dress Barn Inc. (NASDAQ: DBRN) rose as high as 9.2% to a yearly his of $22.42 after the women’s clothing retailer announced earnings of $0.37, beating analysts estimates.

The J.M. Smucker Company (NYSE: SJM) rose as high as 6.3% to a yearly high of $56.86  after the jam and peanut butter maker reported earnings of $1.222 per share, beating analyst estimates.  

Merck & Co. (NYSE: MRK) rose nearly 4% to a yearly high of $36.67 after the pharmaceutical company announced that drug Elonva was recommended for treatment of the ovaries in the European Union.

Garrett W. McIntyre

Posted on: November 20, 2009 – 4:11 pm in Earnings, Food, Pharmaceuticals, Retail, , , ,

FDA: Thin Blood, Sour Stomach (AZN)(BMY)(SNY)

The FDA is routinely criticized for being a poor steward of drug research and pharmaceutical side effects. The agency proved once again why much of the criticism is justified.

The FDA today said that two drugs, each of which has been on the market for many years, react badly when taken together. It is a wonder it took so long to figure this out since each of the drugs is very widely used. Read More »

Posted on: November 17, 2009 – 11:37 am in Pharmaceuticals, , ,

52-Week High Club (FDX, LNY, MRK, GOOG)

FedEx Corp. (NYSE: FDX) over 3% to a yearly high of $84.92.  Barron’s reported that the package delivery company may rise as high as $100 dollars according to a survey of investors and analysts.

Landry’s Restaurants Inc. (NYSE: LNY) rose over 20% to a yearly high of $20.23.  After last week’s buyout proposal from the company’s chief executive Bill Ackman’s Pershing Square Capital has reported a stake in the company and has divulged its opposition to the buyout offer.

Merck & Co. Inc. (NYSE: MRK) rose over 2.5% to a yearly high of $34.35.  The company’s Human Health President Keneth Frazier told CNBC that it would not pull Vytorin and Zetia, the company’s cholesterol medications, off of the market.

Google Inc. (NASDAQ: GOOG) rose close to 1% to a yearly high of $576.99.  The TechCruch blog put out a piece on Sunday reporting that Google had hired Microsoft’s (NASDAQ: MSFT) former director of new business development.

Garrett W. McIntyre

Posted on: November 16, 2009 – 4:02 pm in Food, Pharmaceuticals, Technology Companies, Transports, , , , ,

Pfizer (PFE) Earns OK

biotechPfizer (NYSE:PFE) had a better quarter than many expected. The drug company reported financial results for third-quarter 2009. Revenues were $11.6 billion, a decrease of 3%. EPS fell to $.51 from $.62 on an adjusted diluted basis.

Revenue from the primary care unit of the company was $5.5 billion, a decline of 4% compared with $5.8 billion in the year-ago quarter. Operationally, Primary revenues were flat, as the strong international performance of Lyrica and Lipitor was offset primarily by lower Lipitor revenues in the U.S. Read More »

Posted on: October 20, 2009 – 8:06 am in Earnings, Pharmaceuticals,

Flu Drug Sales Take Off

biotechRoche earnings offered hope to the scores of biotech companies working on H1N1 treatments. The big pharma firm, which makes most of its money from cancer treatments, profited from the spread of the flu.

Roche raised its 2009 sales guidance for the second time this year, after reporting a better-than-expected 9.7% rise in third-quarter sales, mainly driven by orders for its anti-viral drug Tamiflu. Read More »

Posted on: October 15, 2009 – 5:39 am in Biotech, Pharmaceuticals

52-Week High Club

Dr. Reddy’s Laboratories (NYSE: RDY) hit a yearly high of $19.32 today, building on momentum initiated yesterday when it was reporeted that the company had received approval from regulators to distribute its high blood pressure drug in the UK.

Red Hat Inc. (NYSE: RHT) hit a yearly high of $27.95 after a wave of analyst upgrades.

OSG America (NYSE: OSP) hit a yearly high of $10.15 after the company announced that it is raising the price that it will pay for all of its publicly traded securities from $8.00 to $10.25.

Pacific Gas & Electric C. (NYSE: PCG) hit a yearly high of $41.75 following an announcement that a unit at its Diablo Canyon nuclear power facility has come back online at full capacity following repairs.  

Garrett W. McIntyre

Posted on: September 24, 2009 – 4:16 pm in Analyst Calls, Nuclear, Pharmaceuticals, Technology Companies, , , ,

Eli Lilly (LLY): America’s Most Stable Companies Keep Cutting Jobs

bearThe rate at which unemployment is growing has slowed recently and is no longer running more than 700,000 jobs lost a month. But, the firings are continuing, even at America’s largest companies, a sign that whatever bright light at the end of the economic tunnel, many firm’s don’t believe it is really there.

Eli Lilly (LLY) said it will let 5,500 people go. At the time of the announcement John C. Lechleiter, Ph.D., chairman and chief executive officer said, “The changes we are announcing today will accelerate the progress of the most exciting pipeline in our history, with more than 60 molecules currently in clinical development.” That gives the impression that management is upbeat about Lilly’s prospects. Read More »

Posted on: September 14, 2009 – 12:18 pm in Labor & Unions, Pharmaceuticals,

The Swine Flu Ferret Defense

biotechThere are dozens of biotech companies and several Big Pharma firms that hope to make money on swine flu treatments, mostly vaccines. They are driven by the WHO’s estimate that nearly a third of the people in the world could contract the disease over the next two years. The really wide big outbreak is supposed to begin in two months, about the time an effective vaccine will come to market. Read More »

Posted on: September 2, 2009 – 5:33 am in Biotech, Pharmaceuticals

Mylan’s (MYL) Deeply Flawed Legal And PR Move

biotechRobert Coury, the CEO of Mylan (MYL), his general counsel, and public affairs staff don’t know how to quit when they are ahead.

The company objected to a story in the Pittsburgh Post-Gazette that raised questions about quality and regulatory problems at the firm’s Mylan’s Morgantown, W.Va., plant.  After a lengthy investigation, Mylan announced that “the final FDA report closes the inspection with no deficiencies found and no FDA “483″ issues. Read More »

Posted on: August 19, 2009 – 11:40 am in Law, Pharmaceuticals,

Fighting Swine Flu The Wal-Mart Way (WMT, AZN, GSK, NOVN, SNY)

WMT

You can just see the TV advertisements now… Wal-Mart and Uncle Sam are “rolling back” swine flu.

The retailer is in talks with federal officials about possibly putting vaccination sites in its stores this fall. It’s a smart idea that should boost Wal-Mart Stores Inc’s (NYSE: WMT) foot traffic, and give the federal government a fighting chance to reach aggressive its inoculation goals, especially in children. Read More »

Posted on: July 30, 2009 – 3:28 pm in Pharmaceuticals, Retail, , , , ,

Europe Steps Up Timetable On Swine Flu Vaccines (VICL, NVAX, BCRX)

earthShares of vaccine makers including Vical Inc. ((Nasdaq: VICL), Novavax Inc. (Nasdaq: NVAX) and BioCryst Pharmaceuticals Inc. (Nasdaq: BCRX) all are up strongly Monday after Europe’s version of the FDA decided to fast-track swine flu vaccine testing, making producers of the yet-to-be-approved inoculations potentially closer to bringing their products to market. Read More »

Posted on: July 27, 2009 – 10:53 am in Biotech, Drug companies, Pharmaceuticals, , ,

Bristol-Myers Gets Key Assets With A Medarex Deal (BMY, MEDX, ABT, JNJ, AMGN, WYE)

biotech

Bristol Myers Inc. (NYSE: BMY) plans to spend $2.4 billion to buy partner Medarex Inc. (Nasdaq: MEDX). It will get a great deal beyond the cancer monoclonal antibody that developed together.

The Medarex pipeline has substantial value.

The monoclonal antibody ipilimumab is by far the main reason that Bristol pulled the trigger. It is currently in Phase III trials for both metastatic melanoma and hormone-refractory prostate cancer. Read More »

Posted on: July 23, 2009 – 9:12 am in Drug companies, Editor's Picks, Mergers and Buy Outs, Pharmaceuticals, , , , ,

Drug Firms Look For Big Profits In Swine Flu Treatments

biotechThe swine flue is apparently more dangerous that the garden variety of flu that has been part of the world health picture for several decades. It is more likely to cause pneumonia and other complications.

Drug companies hate to be left out of treating widespread diseases, so several are racing to get out vaccines for swine flu for release are soon as the beginning of next year. Read More »

Posted on: July 23, 2009 – 5:06 am in Drug companies, Pharmaceuticals,

The Next Blockbuster Drugs: A $170 Billion Opportunity

biotech

Safety and efficacy data are critical to drug candidates. But what really makes a potential drug attractive is strong top-line data, a new biotech-based treatment, and a massive potential market.

With help from Thomson Pharma and our own backlog of coverage, BioHealthInvestor.com, a 247wallst.com website, sought to find the most promising biopharmaceutical candidate from both biotech and pharmaceutical companies in each of the top 10 most prevalent medical conditions in the U.S. Read More »

Posted on: July 22, 2009 – 4:01 am in Biotech, Drug companies, Editor's Picks, Pharmaceuticals, , , , , , , , , , , , , , , , , , , , ,

Apple (APPL) And Caterpillar (CAT): Someone, Somewhere, Somehow, Is Spending Money

appleApple’s beat Wall St. consensus figures by posting earnings per share of $1.35 compared to Wall St. expectations of $1.17. The company also produced revenue of $8.33 billion, up 12% from last year. The recession must be over.

Apple’s figures are a conundrum. The firm sold 5.2 million iPhones in the quarter ending in June. A lot of people are using unemployment benefits to buy the handsets, or people who are supposed to be saving money and not spending it, according to the government, are running up the balances on their credit cards as if the economic downturn never happened. Read More »

Posted on: July 22, 2009 – 3:50 am in Banking, Consumer Electronics, Drug companies, Earnings, Editor's Picks, Food, Healthcare, PC Companies, Pharmaceuticals, Wireless, , , , ,

Healthcare: Another Scheme To Tax The “Rich”

uncle samHaving money is not what it used to be. According to several media reports, the billionaire mayor of New York City, Michael Bloomberg, lost millions of dollars in the market downturn. He has apparently had to lay off some of his private staff and rent out his vacation home in Wellington, Florida.

Now that the well-to-do have lost hundreds of billions of dollars in the stock and real estate markets, the Congress appears ready to call on them to fund the new health care reform package. Read More »

Posted on: July 11, 2009 – 7:26 am in Economy, Healthcare, Medical, Pharmaceuticals

Media Digest 7/7/2009 Reuters, WSJ, NYTimes, FT, Bloomberg

newspaperReuters:   Japanes Topix index is expect to rise to 1,000.

Reuters:   The US may need a second stimulus package.

Reuters:   Hospitals have agreed to contribute $155 billion over ten years to help with the healthcare package.

Reuters:   Treasury is ready to push Wall St. on starting a consumer protection agency.

Reuters:   Lear filed for bankruptcy. Read More »

Posted on: July 7, 2009 – 2:55 am in Autos, Banking, Earnings, Healthcare, Luxury, Mergers and Buy Outs, Pharmaceuticals, Press Digest, Wireless, , , , , , , ,

The Best Short-Selling Opportunities Of The Year (C)(GE)(F)(SBUX)(SIRI)

angrybearThere is still some conversation about the federal government restricting short-selling activity in certain stocks. The counterargument to these restrictions is that short selling plays an important role in the valuation of securities by efficiently allowing investors to bet that a stock will fall as readily as they can bet that it will rise. Short sellers have the reputation, whether deserved or not, for trying to manipulate information about public companies with the hope of driving their prices down. That may be true.

24/7 Wall St. has come up with a list of the best short-selling opportunities between now and the end of the year. The list was chosen based on: 1) trading volume, 2) the total short position in the stock over the first half of the year, 3) a history of the short position in these stocks rising or falling rapidly, and 4) stocks in companies that tend to move on news throughout the year and not just on earnings information. Read More »

Posted on: July 5, 2009 – 5:54 pm in Airlines, Analyst Calls, Autos, Banking, Biotech, Casinos, Conglomerates, Consumer Electronics, Dividend, Drug companies, Editor's Picks, FDA, Green Biz, Hardware, Healthcare, Infrastructure, Internet, Large Cap Stocks, Medical, PC Companies, Pharmaceuticals, Private Equity, Retail, Short Interest, Software, Technology, Turnarounds, Wireless, , , , , , , , , , , , , , , , , , , ,

Anti-Smoking Drugs Could Cause Suicide (PFE)(GSK)

magazinIt is hard to say whether a person is better off stopping smoking and lessening their chances of a heart attack or killing themselves.  Some of the anti-smoking drugs from Pfizer (PFE) and GlaxoSmithKline (GSK) can have terrible side effects.  The drugs are Chantix, made by Pfizer, and Zyban, made by GlaxoSmithKline. Inexplicably, the FDA will allow the treatments to stay on the market.

The New York Times reports that “Federal drug regulators warned Wednesday that patients taking two popular drugs to stop smoking should be watched closely for signs of serious mental illness, as reports mount of suicides among the drugs’ users.” Read More »

Posted on: July 2, 2009 – 4:59 am in Pharmaceuticals, ,

Media Digest 7/1/2009 Reuters, WSJ, NYTimes, FT, Bloomberg

newspaperReuters:   California raced to approve a state budget its cutting deficit.

Reuters:   Ten more people may face charges in Madoff case.

Reuters:   Gannett (GCI) is laying off 1,000 more people.

Reuters:   China will delay a web filter for PCs sold in the country.

Reuters:   B of A’s (BAC) asset management unit got low bids.

Reuters:   Monster’s June job index fell.

Read More »

Posted on: July 1, 2009 – 2:54 am in Autos, Banking, Biotech, China, Commodities, Compensation, Conglomerates, Drug companies, Entertainment, FDA, Internet, Management Change, Metals, Pharmaceuticals, Press Digest, Turnarounds, , ,